Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Otsuka Pharmaceutical Development & Commercialization, Inc.

News headline image
Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026
From Otsuka Pharmaceutical Development & Commercialization, Inc.
Via Business Wire
News headline image
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Alzheimer’s Dementia
From Otsuka Pharmaceutical Development & Commercialization, Inc.
Via Business Wire
News headline image
Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder
From Otsuka Pharmaceutical Development & Commercialization, Inc.
Via Business Wire
News headline image
Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer’s dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference
From Otsuka Pharmaceutical Development & Commercialization, Inc.
Via Business Wire
News headline image
Otsuka Pharmaceutical and Lundbeck to Present Phase 3 Data for Brexpiprazole in Patients with Alzheimer’s Dementia at AAIC 2022
From Otsuka Pharmaceutical Development & Commercialization, Inc.
Via Business Wire
News headline image
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline
From Otsuka Pharmaceutical Development & Commercialization, Inc.
Via Business Wire
News headline image
Otsuka Signs Three-Year Collaboration with Holmusk to Enhance Digital Health and Data Analytics for Global Behavioral Health Programs
From Otsuka Pharmaceutical Development & Commercialization, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.